Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER_GOV 1OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gynecologic 1

Conditions

Small Cell Lung Carcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × belotecan × Clear all
NCT01497873 2018-12-27

A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer

Chong Kun Dang Pharmaceutical

Phase 2 Completed
164 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01630018 2016-09-22

Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

Chong Kun Dang Pharmaceutical

Phase 2 Completed
141 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT01022671 2016-01-28

Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy

Chong Kun Dang Pharmaceutical

Phase 2 Completed
52 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡